Reta20 new – bdresearchlabs.com

Reta20

A research-grade triple agonist peptide engineered for simultaneous activation of GLP-1, GIP and glucagon receptors — investigating fat metabolism, satiety regulation and energy expenditure under controlled clinical observation.

Compound

Retatrutide-20

Dosage

5 mg / vial

Purity

≥ 99.2%

SPEC.001

Lyophilized · reconstitute with bacteriostatic water

01 / 08

Compound Overview

A next-generation tri-agonist peptide.

Reta20 is a research-grade synthetic peptide engineered as a unimolecular agonist of three metabolic receptors: GLP-1, GIP and glucagon. It belongs to the retatrutide class of investigational compounds developed for the study of obesity, type-2 diabetes and metabolic syndrome.

By coordinating three signaling pathways simultaneously, Reta20 produces a synergistic metabolic profile distinct from single- or dual-agonist analogues. All material is supplied for in-vitro and laboratory research applications under the British Dragon Gold Tier quality assurance standard.

Class

Triple receptor agonist

Targets

GLP-1 · GIP · Glucagon

Form

Lyophilized powder

Tier

Gold · Research

02 / 08

Mechanism of Action

Three receptors. One molecule.

Coordinated activation of GLP-1, GIP and glucagon receptors drives glycemic regulation, appetite signalling and thermogenic energy expenditure.

FIG. 02 — Receptor Cascade

Schematic

R-01

GLP-1 Receptor

R-02

GIP Receptor

Adipose modulation · glucose uptake

R-03

Glucagon Receptor

Hepatic lipolysis · thermogenesis

03 / 08

External Analysis

Mechanism Breakdown — 3rd Party Analysis

This video provides an external overview of how Reta20 interacts with GLP-1, GIP and glucagon receptors to influence fat metabolism and energy expenditure.

External Source

Embed · Placeholder

04 / 08

Key Takeaways

Four pillars of metabolic research.

A condensed view of the principal mechanisms observed across published preclinical and Phase II investigational data.

01 Triple receptor agonism

Simultaneous activation of GLP-1, GIP and glucagon pathways.

02 Appetite suppression

Central and peripheral satiety signalling reduces caloric intake.

03 Increased energy expenditure

Glucagon-mediated thermogenesis elevates basal metabolic rate.

04 Fat metabolism support

Hepatic and adipose lipolysis with preferential fat-mass reduction.

05 / 08

Dosing Protocol

Titration schedule.

Standard research titration model. Adjust under qualified clinical observation only. Not for human therapeutic use.

Phase 01

Wk 1 — 4

2 mg

Once weekly

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

4 mg

Once weekly

Standard titration step

Phase 03

Wk 9 — 12

8 mg

Once weekly

Maintenance evaluation

Phase 04

Wk 13+

12 mg

Once weekly

Optional research extension

06 / 08

Expected Effects

Observed effects matrix.

Aggregated observations from published research literature on the retatrutide compound class.

Body Weight

−24.2%

@ 48 weeks · 12 mg cohort

Visceral Fat

−31%

DEXA composition trial data

HbA1c

−2.16%

Mean reduction at maintenance

Energy Expenditure

+8.5%

Resting metabolic rate

Appetite Score

−42%

Reported satiety scale

Lipid Profile

Improved

Triglycerides · LDL reduction

07 / 08

Safety / Disclaimer

Research use only.

Reta20 is supplied strictly for in-vitro laboratory research and biochemical analysis. It is not intended for human consumption, diagnostic use, veterinary application or therapeutic administration of any kind.

Handling must be performed by qualified personnel in compliance with applicable institutional and jurisdictional safety standards. The information contained on this protocol sheet is provided for educational and reference purposes only and does not constitute medical advice.

Not for human use
Store at 2–8 °C, protected from light

Reconstitute under aseptic conditions
Document all research observations

08 / 08

British Dragon · Catalogue

Gold Tier Catalogue

Explore the full British Dragon research line.

Premium-tier compounds engineered for serious metabolic, longevity and performance research programs.